Temporal trends in relative survival and excess mortality among US adults with lymphoid malignancies

Clicks: 21
ID: 329705
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #110 of 408 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 408 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Lymphoid malignancies comprise a heterogeneous group of diseases with diverse treatment approaches and outcomes. Therapeutic advances have been uneven across subtypes, and contemporary data on temporal changes in mortality remain limited. We assessed trends in survival and excess mortality using US population-based data. METHODS: This retrospective cohort study included patients newly diagnosed with lymphoid malignancies during 2001-2018 from 17 registries of the Surveillance, Epidemiology, and End Results program. We estimated 5-year relative survival and modeled excess mortality using Poisson regression. RESULTS: Five-year relative survival improved and excess mortality decreased over time for precursor lymphoid malignancies, Hodgkin lymphomas, and most mature B-cell lymphomas. Among subtypes with declining excess mortality, average reductions ranged from 6% to 20% per calendar period. The largest declines were observed for lymphocyte-rich Hodgkin lymphoma (20% reduction), followed by B-cell (19% reduction) and T-cell lymphoblastic leukemia/lymphoma (18% reduction). In contrast, excess mortality for certain aggressive mature T-cell lymphomas showed little or no improvement, including adult T-cell leukemia/lymphoma, peripheral T-cell lymphoma not otherwise specified, and angioimmunoblastic T-cell lymphoma. Subgroup analyses suggested more pronounced excess mortality declines among younger adults compared to middle-aged or older adults for several subtypes. CONCLUSION: Most lymphoid malignancies showed improvements in survival and declines in excess mortality over time. However, certain rare and aggressive subtypes exhibited limited or no progress. These findings may reflect overall benefits from advancements in treatment and supportive care, while identifying research priorities for lymphoid subtypes with unmet survival needs.
Reference Key
openalex_W7214189943 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bryan Valcarcel, Veronica Leautaud, Michelle A.T. Hildebrandt, Maria Alma Rodriguez, Dustin McCurry, Sachet Ashok Shukla, Ethel Cesarman, Brady Beltrán, Pilar Quiñones, Denisse Castro, Sally Paredes, Jule Vasquez, Carlos Barrionuevo Cornejo, Christopher R. Flowers, Luis Malpica
Are you one of these authors? Claim your profile
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag341
URL
https://doi.org/10.1093/jnci/djag341
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.